X0306 4 2022-05-19 0 0001662774 Cortexyme, Inc. CRTX 0001509669 Low Philip S C/O CORTEXYME, INC. 269 EAST GRAND AVE. SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2022-05-19 4 A 0 455309 A 455309 D Common Stock 2022-05-19 4 A 0 63974 A 63974 I By Philip S. Low Revocable Trust Stock Option (right to buy) 3.30 2022-05-19 4 A 0 22058 0.00 A 2032-05-18 Common Stock 22058 22058 D On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. The shares subject to the option shall vest in equal annual installments over the three-year period following the grant date of May 19, 2022. /s/ Chris Lowe, Attorney-in-Fact for Philip S. Low 2022-05-23